August 14, 2006—Gilead Sciences announced Friday that developing nations would soon get the first one pill, once-a-day HIV treatment. The FDA approved the drug, Atripla (efavirenz, emtricitabine and tenofovir), for U.S. use in July. Gilead will team with Merck & Co. Inc. to distribute the treatment globally; no timeline has been established.